DCB/TCCNE MEET-UP

DCB 數位健康國際加速器波士頓鏈結

Boston International Practice

財團法人生物技術開發中心NBIC將於2019年6月24日(一)與波士頓TCCNE合作舉辦創新聚會(Meet-up),並帶領今年度加速器與育成會員前往波士頓進行海外資 金與市場資源鏈結行程。 Taiwan leading preclinical drug research institute, Development Center of

Biotechnology, took the wind of global biomedical innovation and launched the first

digital health accelerator in Taiwan. We are very pleased to bring our startups to

Boston to show their brilliant and innovative ideas and solution to make great

impacts on the future healthcare generation.

We want to invite you to join this meet-up and meet the future starts!!

【主辦單位/Hoster 】

Development Center of Biotechnology/NanKang Biotech Incubation Center

【合辦單位/Co-hoster】

Taiwan Chamber of Commerce of New England

【活動時間/Date 】

June 24th (Monday) 13:30pm~17:00pm

【活動地點/Location】  

Mezzanine, 99 Summer St Boston MA 02110

Time Activity Speaker

13:30-14:00 Registration and Networking

14:00-14:30 VC talk Mr.Shaoyu Chang, VP

of FC Capital

14:30-14:40 DCB/NBIC Talk DCB Staff

14:40-14:50 Pitch 1 (5mins pitch + 5 mins QA) MDTK

14:50-15:00 Pitch 2 (5mins pitch + 5 mins QA) GenomeFrontier

15:00-15:10 Pitch 3 (5mins pitch + 5 mins QA) ZBL

15:10-17:00 Networking

Startup Briefing

1. MedicalTek CO., Ltd Brady Chen, BD Head

MDTK solution, MonoStereo® 3D, is the best 2D to 3D endoscope visualization

system on the market. It offers the easy-set, easy-alter adjustable 3D effects to

support accurate and precise surgery.

This solution is now applied in their partner Taiwan hospital and has conducted test

projects in one French hospital. They are expected to get FDA approval in 2019.

They are now in their A round stage and looking for B round funding.

Website: https://www.medicaltek.biz/

2. GenomeFrontier Therapeutics Dr. Sareina Wu, CEO

Established in 2018, GenomeFrontier leverages their 4

proprietary non-viral based gene and cell engineering platforms in CAR-T cell

therapies for cancer treatment to address the current challenges.

To demonstrate their disruptive CAR-T cell therapy with high efficacy, safety and cost

competitive, the 1st pipeline GF-CART01 is under-developing to target

CD19-positive lymphoma to prove the success of integration of these four

platforms, followed by our ultimate goal to cure solid tumors.

Through collaborating with the global elites, these platforms can be adapted on the

various CAR -immune gene therapy and from autologous to allogeneic mode.

Website: https://www.genomefrontier.com/

3. Zenith BioDesign Lab/ZBL Dr. Lai Kuei-Tai, CEO

ZBL’s provides a platform technology to reduce on-target off-tumor toxicity for the

biological drugs used in clinical and developing in clinical trials.

The ZBL Universal Masked Platform Technology:

1. To increase therapeutic window of conventional antibody drug Conjugates (ADCs)

while reducing their on-target/off tumor toxicity.

2. Opening a new strategy for biologicals drug development: one mask for all

targeting biological drugs.  

Website: under developing